Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Keywords

Coronavirus disease 2019 (COVID-19)MedicinePlaceboSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakDouble blindBetacoronavirusClinical trialVirologyInternal medicineAlternative medicineOutbreakPathology

Affiliated Institutions

Related Publications

Remdesivir for the Treatment of Covid-19 — Final Report

John H. Beigel , Kay M Tomashek , Lori E. Dodd +37 more

Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory trac...

2020 New England Journal of Medicine 7559 citations

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Chih‐Cheng Lai , Tzu-Ping Shih , Wen‐Chien Ko +2 more

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at ...

2020 International Journal of Antimicrobia... 6277 citations

Characteristics of SARS-CoV-2 and COVID-19

Ben Hu , Hua Guo , Peng Zhou +1 more

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute re...

2020 Nature Reviews Microbiology 5269 citations

Clinical and immunological features of severe and moderate coronavirus disease 2019

Guang Chen , Di Wu , Wei Guo +17 more

BACKGROUNDSince December 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and is...

2020 Journal of Clinical Investigation 4983 citations

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Bindu Bennet , Jayanthi Wolf , Rodrigo Laureano +1 more

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an ur...

2020 Toxicologic Pathology 47 citations

Publication Info

Year: 2020
Type: article
Volume: 395
Issue: 10236
Pages: 1569-1578
Citations: 3615
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3615

OpenAlex

Cite This

APA Style

                            
                                
                                    Yeming Wang, 
                                
                                    Dingyu Zhang, 
                                
                                    Guanhua Du
                                
                                et al.
                            
                            (2020). 
                            Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. 
                            The Lancet
                            , 395
                            (10236)
                            , 1569-1578.
                            https://doi.org/10.1016/s0140-6736(20)31022-9
                        

Identifiers

DOI: 10.1016/s0140-6736(20)31022-9